

SATELLITE CME SYMPOSIUM

Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

Provided by RMEI Medical Education, LLC.



Supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

WEDNESDAY, SEPTEMBER 8, 2021

12:00 – 13:00 MDT / 14:00 – 15:00 EDT
20:00 – 21:00 CEST



WHO SHOULD ATTEND?

This activity is intended for medical oncology, pathology, and pulmonology clinicians attending the virtual IASLC 2021 World Conference on Lung Cancer meeting and who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

EXPERT FACULTY



Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)
Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China



Shirish M. Gadgeel, MD
Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI



Antonio Passaro, MD, PhD
Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Analyze the predictive/prognostic significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
- Apply optimal diagnostic strategies for identifying NSCLC with EGFR exon 20 insertions
- Assess clinical trial data regarding new and emerging treatment options for advanced NSCLC with EGFR exon 20 insertions
- Employ appropriate techniques to manage adverse events associated with EGFR inhibition

PROGRAM AGENDA

12:00 – 12:05 MDT	Welcome and Introductions <i>Prof. Tony S.K. Mok (Chair)</i>
12:05 – 12:20 MDT	EGFR Insertion Mutations in NSCLC: Why and How Do We Test? <i>Dr. Shirish M. Gadgeel</i>
12:20 – 12:40 MDT	New and Emerging Therapies for NSCLC with EXON 20 INS Mutations <i>Prof. Tony S.K. Mok (Chair)</i>
12:40 – 12:50 MDT	Managing Toxicity with Anti-EGFR Exon 20 Agents <i>Dr. Antonio Passaro</i>
12:50 – 13:00 MDT	Audience Q&A and Closing Remarks <i>All Faculty</i>

JOINT ACCREDITATION STATEMENT



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationship for all persons in control of content before the learner engages in the education.

FEE INFORMATION

There is no fee for this educational activity. Individuals must be registered for the IASLC 2021 WCLC in order to attend this symposium.